Regeneron: What we know about the experimental coronavirus drug ...

Globalnews.ca - 08 Oct 2020
What is it? For starters, it's not actually a cure, it's a therapeutic treatment still under analysis. Click to play video 'Coronavirus: Trump says COVID-19 was 'blessing ...

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

Reuters - 25 Apr 2024
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth ...

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration

Genetic Engineering & Biotechnology News - 25 Apr 2024
Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration ...

Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

MarketWatch - 26 Apr 2024
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors ...

Regeneron signs Mammoth gene editing deal worth $100M upfront

Fierce Biotech - 25 Apr 2024
Regeneron signs Mammoth gene editing deal worth $100M upfront ...

Sales of Roche's juggernaut Vabysmo rout the analyst consensus

FiercePharma - 24 Apr 2024
Sales of Roche's juggernaut Vabysmo rout the analyst consensus ...

Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct)

Bloomberg Law - 26 Apr 2024
Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) ...

Regeneron and Mammoth announce gene editing partnership worth $370m per target

PMLiVE - 26 Apr 2024
Regeneron and Mammoth announce gene editing partnership worth $370m per target ...

Regeneron and Mammoth team up to develop gene editing therapies

Pharmaceutical Technology - 26 Apr 2024
Regeneron and Mammoth team up to develop gene editing therapies ...

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery

BioSpace - 25 Apr 2024
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery ...

Why Regeneron (REGN) Could Beat Earnings Estimates Again

Yahoo Canada Finance - 16 Apr 2024
Why Regeneron (REGN) Could Beat Earnings Estimates Again ...

Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines

MedCity News - 25 Apr 2024
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines ...

Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch

Investopedia - 11 Apr 2024
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch ...

Regeneron inks $100M deal to develop gene-editing therapies

Crain's New York Business - 26 Apr 2024
Regeneron inks $100M deal to develop gene-editing therapies ...

AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

Reuters - 25 Apr 2024
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study ...

Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences

MarketWatch - 25 Apr 2024
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences ...

Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent

FiercePharma - 26 Apr 2024
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent ...

Regeneron to defend against DOJ complaint on drug-price manipulation

Reuters - 15 Apr 2024
Regeneron to defend against DOJ complaint on drug-price manipulation ...

Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market

MarketWatch - 23 Apr 2024
Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market ...

Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare

FiercePharma - 11 Apr 2024
Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare ...

Regeneron